Amelioration of ischemic brain injury in rats with human umbilical cord blood stem cells: Mechanisms of action

Laura L. Hocum Stone, Feng Xiao, Jessica Rotschafer, Zhenhong Nan, Mario Juliano, Cyndy D. Sanberg, Paul R. Sanberg, Nicole Kuzmin-Nichols, Andrew Grande, Maxim C J Cheeran, Walter C. Low

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Despite the high prevalence and devastating outcome, there remain a few options for treatment of ischemic stroke. Currently available treatments are limited by a short time window for treatment and marginal efficacy when used. We have tested a human umbilical cord blood-derived stem cell line that has been shown to result in a significant reduction in stroke infarct volume as well as improved functional recovery following stroke in the rat. In the present study we address the mechanism of action and compared the therapeutic efficacy of high- versus low-passage nonhematopoietic umbilical cord blood stem cells (nh-UCBSCs). Using the middle cerebral arterial occlusion (MCAo) model of stroke in Sprague–Dawley rats, we administered nh-UCBSC by intravenous (IV) injection 2 days following stroke induction. These human cells were injected into rats without any immune suppression, and no adverse reactions were detected. Both behavioral and histological analyses have shown that the administration of these cells reduces the infarct volume by 50% as well as improves the functional outcome of these rats following stroke for both high- and low-passaged nh-UCBSCs. Flow cytometry analysis of immune cells present in the brains of normal rats, rats with ischemic brain injury, and ischemic animals with nh-UCBSC treatment confirmed infiltration of macrophages and T cells consequent to ischemia and reduction to normal levels with nh-UCBSC treatment. Flow cytometry also revealed a restoration of normal levels of microglia in the brain following treatment. These data suggest that nh-UCBSCs may act by inhibiting immune cell migration into the brain from the periphery and possibly by inhibition of immune cell activation within the brain. nh-UCBSCs exhibit great potential for treatment of stroke, including the fact that they are associated with an increased therapeutic time window, no known ill-effects, and that they can be expanded to high numbers for, and stored for, treatment.

Original languageEnglish (US)
Pages (from-to)1473-1488
Number of pages16
JournalCell transplantation
Volume25
Issue number8
DOIs
StatePublished - Jan 1 2016

Fingerprint

Stem cells
Fetal Blood
Brain Injuries
Rats
Brain
Blood Cells
Blood
Stem Cells
Stroke
Flow cytometry
Therapeutics
Flow Cytometry
T-cells
Macrophages
Infiltration
Microglia
Restoration
Intravenous Injections
Stroke Volume
Animals

Keywords

  • Immune response
  • Ischemia
  • Stem cells
  • Stroke

Cite this

Amelioration of ischemic brain injury in rats with human umbilical cord blood stem cells : Mechanisms of action. / Hocum Stone, Laura L.; Xiao, Feng; Rotschafer, Jessica; Nan, Zhenhong; Juliano, Mario; Sanberg, Cyndy D.; Sanberg, Paul R.; Kuzmin-Nichols, Nicole; Grande, Andrew; Cheeran, Maxim C J; Low, Walter C.

In: Cell transplantation, Vol. 25, No. 8, 01.01.2016, p. 1473-1488.

Research output: Contribution to journalArticle

Hocum Stone, Laura L. ; Xiao, Feng ; Rotschafer, Jessica ; Nan, Zhenhong ; Juliano, Mario ; Sanberg, Cyndy D. ; Sanberg, Paul R. ; Kuzmin-Nichols, Nicole ; Grande, Andrew ; Cheeran, Maxim C J ; Low, Walter C. / Amelioration of ischemic brain injury in rats with human umbilical cord blood stem cells : Mechanisms of action. In: Cell transplantation. 2016 ; Vol. 25, No. 8. pp. 1473-1488.
@article{4e8f5da898b24c969e2086617bf6fb74,
title = "Amelioration of ischemic brain injury in rats with human umbilical cord blood stem cells: Mechanisms of action",
abstract = "Despite the high prevalence and devastating outcome, there remain a few options for treatment of ischemic stroke. Currently available treatments are limited by a short time window for treatment and marginal efficacy when used. We have tested a human umbilical cord blood-derived stem cell line that has been shown to result in a significant reduction in stroke infarct volume as well as improved functional recovery following stroke in the rat. In the present study we address the mechanism of action and compared the therapeutic efficacy of high- versus low-passage nonhematopoietic umbilical cord blood stem cells (nh-UCBSCs). Using the middle cerebral arterial occlusion (MCAo) model of stroke in Sprague–Dawley rats, we administered nh-UCBSC by intravenous (IV) injection 2 days following stroke induction. These human cells were injected into rats without any immune suppression, and no adverse reactions were detected. Both behavioral and histological analyses have shown that the administration of these cells reduces the infarct volume by 50{\%} as well as improves the functional outcome of these rats following stroke for both high- and low-passaged nh-UCBSCs. Flow cytometry analysis of immune cells present in the brains of normal rats, rats with ischemic brain injury, and ischemic animals with nh-UCBSC treatment confirmed infiltration of macrophages and T cells consequent to ischemia and reduction to normal levels with nh-UCBSC treatment. Flow cytometry also revealed a restoration of normal levels of microglia in the brain following treatment. These data suggest that nh-UCBSCs may act by inhibiting immune cell migration into the brain from the periphery and possibly by inhibition of immune cell activation within the brain. nh-UCBSCs exhibit great potential for treatment of stroke, including the fact that they are associated with an increased therapeutic time window, no known ill-effects, and that they can be expanded to high numbers for, and stored for, treatment.",
keywords = "Immune response, Ischemia, Stem cells, Stroke",
author = "{Hocum Stone}, {Laura L.} and Feng Xiao and Jessica Rotschafer and Zhenhong Nan and Mario Juliano and Sanberg, {Cyndy D.} and Sanberg, {Paul R.} and Nicole Kuzmin-Nichols and Andrew Grande and Cheeran, {Maxim C J} and Low, {Walter C.}",
year = "2016",
month = "1",
day = "1",
doi = "10.3727/096368916X691277",
language = "English (US)",
volume = "25",
pages = "1473--1488",
journal = "Cell Transplantation",
issn = "0963-6897",
publisher = "Cognizant Communication Corporation",
number = "8",

}

TY - JOUR

T1 - Amelioration of ischemic brain injury in rats with human umbilical cord blood stem cells

T2 - Mechanisms of action

AU - Hocum Stone, Laura L.

AU - Xiao, Feng

AU - Rotschafer, Jessica

AU - Nan, Zhenhong

AU - Juliano, Mario

AU - Sanberg, Cyndy D.

AU - Sanberg, Paul R.

AU - Kuzmin-Nichols, Nicole

AU - Grande, Andrew

AU - Cheeran, Maxim C J

AU - Low, Walter C.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Despite the high prevalence and devastating outcome, there remain a few options for treatment of ischemic stroke. Currently available treatments are limited by a short time window for treatment and marginal efficacy when used. We have tested a human umbilical cord blood-derived stem cell line that has been shown to result in a significant reduction in stroke infarct volume as well as improved functional recovery following stroke in the rat. In the present study we address the mechanism of action and compared the therapeutic efficacy of high- versus low-passage nonhematopoietic umbilical cord blood stem cells (nh-UCBSCs). Using the middle cerebral arterial occlusion (MCAo) model of stroke in Sprague–Dawley rats, we administered nh-UCBSC by intravenous (IV) injection 2 days following stroke induction. These human cells were injected into rats without any immune suppression, and no adverse reactions were detected. Both behavioral and histological analyses have shown that the administration of these cells reduces the infarct volume by 50% as well as improves the functional outcome of these rats following stroke for both high- and low-passaged nh-UCBSCs. Flow cytometry analysis of immune cells present in the brains of normal rats, rats with ischemic brain injury, and ischemic animals with nh-UCBSC treatment confirmed infiltration of macrophages and T cells consequent to ischemia and reduction to normal levels with nh-UCBSC treatment. Flow cytometry also revealed a restoration of normal levels of microglia in the brain following treatment. These data suggest that nh-UCBSCs may act by inhibiting immune cell migration into the brain from the periphery and possibly by inhibition of immune cell activation within the brain. nh-UCBSCs exhibit great potential for treatment of stroke, including the fact that they are associated with an increased therapeutic time window, no known ill-effects, and that they can be expanded to high numbers for, and stored for, treatment.

AB - Despite the high prevalence and devastating outcome, there remain a few options for treatment of ischemic stroke. Currently available treatments are limited by a short time window for treatment and marginal efficacy when used. We have tested a human umbilical cord blood-derived stem cell line that has been shown to result in a significant reduction in stroke infarct volume as well as improved functional recovery following stroke in the rat. In the present study we address the mechanism of action and compared the therapeutic efficacy of high- versus low-passage nonhematopoietic umbilical cord blood stem cells (nh-UCBSCs). Using the middle cerebral arterial occlusion (MCAo) model of stroke in Sprague–Dawley rats, we administered nh-UCBSC by intravenous (IV) injection 2 days following stroke induction. These human cells were injected into rats without any immune suppression, and no adverse reactions were detected. Both behavioral and histological analyses have shown that the administration of these cells reduces the infarct volume by 50% as well as improves the functional outcome of these rats following stroke for both high- and low-passaged nh-UCBSCs. Flow cytometry analysis of immune cells present in the brains of normal rats, rats with ischemic brain injury, and ischemic animals with nh-UCBSC treatment confirmed infiltration of macrophages and T cells consequent to ischemia and reduction to normal levels with nh-UCBSC treatment. Flow cytometry also revealed a restoration of normal levels of microglia in the brain following treatment. These data suggest that nh-UCBSCs may act by inhibiting immune cell migration into the brain from the periphery and possibly by inhibition of immune cell activation within the brain. nh-UCBSCs exhibit great potential for treatment of stroke, including the fact that they are associated with an increased therapeutic time window, no known ill-effects, and that they can be expanded to high numbers for, and stored for, treatment.

KW - Immune response

KW - Ischemia

KW - Stem cells

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=84982921067&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982921067&partnerID=8YFLogxK

U2 - 10.3727/096368916X691277

DO - 10.3727/096368916X691277

M3 - Article

C2 - 26996530

AN - SCOPUS:84982921067

VL - 25

SP - 1473

EP - 1488

JO - Cell Transplantation

JF - Cell Transplantation

SN - 0963-6897

IS - 8

ER -